A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas-MedSci.cn

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Bejar, R; Zhang, HY; Rastgoo, N; Benbatoul, K; Jin, YY; Thayer, M; Sheng, S; Chow, GK; Montalvo-Lugo, V; Marango, J; Howell, SB; Rice, WG

BLOOD, 2020; 136 ():

科室
- - 订阅+
  - 更多科室
工具
服务